I’m Tired Again, and I’m Sure You’ve Been There
Are you tired? Really tired? Me, too. Most of us with multiple sclerosis are. How many is most? A small new study of 44 people with one of the progressive forms of MS…
The MS Wire — Ed Tobias
People say to write what you know and Ed Tobias knows about MS. He’s lived with the illness since 1980, when he was 32 years old. Ed’s a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. He’s also the author of “The Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.” Ed and his wife split their time between the Washington, D.C. suburbs and Florida’s Gulf Coast, trying to follow the sun.
Featured Post
After more than 7 years, ‘The MS Wire’ column is moving on
This is my 823rd column for Multiple Sclerosis News Today. It is also my last. Over the past seven and a half years, I’ve written about multiple sclerosis (MS) fatigue and…
Read more
MS News that Caught My Eye Last Week: Ofatumumab, Zeposia, Early Symptoms, New App
FDA Extends Review of Ofatumumab for Relapsing MS to September The U.S. Food and Drug Administration (FDA) was expected to make a decision about ofatumumab, a self-administered injection of a monoclonal antibody, by…
Another Medication, Zeposia, Joins the MS Treatment Arsenal
By my unofficial count, disease-modifying therapy No. 19 has just become available to people with multiple sclerosis in the U.S. The U.S. Food and Drug Administration (FDA) approved Zeposia (ozanimod) in late March.
MS News that Caught My Eye Last Week: Pollution and MS, ATA188, Ofatumumab, Zeposia
Air Pollution of Urban Life Raises MS Risk, Study from Italy Suggests I grew up in New York City. It’s hard to get more urban than that. There weren’t many factories spewing pollution,…
Am I Having an MS Relapse?
As I sit down to write this week’s column, it’s hard for me to concentrate. I’d planned to write about new MS mobile apps, but I can’t get my brain to focus on the…
MS News that Caught My Eye Last Week: Vascular Disease, Glatopa vs. Copaxone, Exercise Tips, MS App
Higher Risk of Vascular Disease Among MS Patients in the UK, Population-based Study Reveals You’d think that people with multiple sclerosis (MS) would be likely to have vascular disease due to the sedentary…
Giving My Laptop the Weekend Off
My favorite line in the “Downton Abbey” TV series, uttered by the dowager played by Maggie Smith, is…
MS News that Caught My Eye Last Week: COVID-19 Data, Epstein-Barr, PoNS Device, Mindfulness
COVID-19 May Not Be Severe in MS Patients, Early Data from Italy Suggest Keep in mind that…
More Evidence Links Epstein-Barr Virus to MS
More support has been added to the belief that a link exists between the Epstein-Barr virus (EBV) and…
MS News that Caught My Eye Last Week: Bafiertam, Stem Cell Transplant Damage, Gilenya Study, NurOwn Benefits
FDA Approves Bafiertam, Tecfidera Bioequivalent, for Relapsing MS This is the second disease-modifying therapy (DMT) OK’d by the FDA in the past few months. Bafiertam is a delayed-release pill that’s similar to Tecfidera,…
A Good News Story About an MS Treatment
I love it when a multiple sclerosis treatment works well for someone. It doesn’t matter if that treatment is a medication, a form of physical therapy, or a diet. Good news is good news.
MS News that Caught My Eye Last Week: Diagnosis by Antibody, Ocrevus After 6 Years, Telemedicine, New DMT Pill
New Nanosensor May Help to Diagnose MS at Early Stages My neurologist likes to say that “brain…
How Has COVID-19 Affected Your MS Life?
I canceled my April blood draw. The protocol for Lemtrada (alemtuzumab) requires lab work each month because the…
News that Caught My Eye Last Week: Ocrevus Infusion Time, Monocytes as a Therapy Target, MS and Work
Shorter Ocrevus Infusion Time Up for Approval in US and Europe One of the drawbacks to infusion…
COVID-19, Joey Cocker, and Me
It’s comforting to have this guy, with his floppy ears, stretched out next to me as I sit…
MS News that Caught My Eye Last Week: Fampyra, COVID-19, Vitamin D, Neurodegeneration
Fampyra, Aid for Walking, Favored for Inclusion in NHS Scotland I used Ampyra, as Fampyra is known…
A Snapshot of COVID-19 and Disease-modifying Therapies
Are people with MS more susceptible than the average person to the coronavirus that causes COVID-19? And if…
MS News that Caught My Eye Last Week: COVID-19 Database, ATA188 Trial Postponed, Teen Smoking, Myelin and Fruit Peels
New Database to Compile COVID-19 Data About People with MS and Related Diseases There are databases in…
My Lemtrada Journey, 2 Years After My Second Round
Happy Lemtrada anniversary to me! It’s been two years since I completed my second round of Lemtrada (alemtuzumab)…
MS News that Caught My Eye Last Week: Exercise, Diet, and Myelin
Regular Exercise ‘Strongly Recommended’ to Ease Fatigue in MS This may seem like a no-brainer. But once…
